An Observational, Multicenter, Open-label Study of YONDELIS + PLD for the Treatment of Patients With Platinum-sensitive Relapse of Ovarian Cancer

Trial Profile

An Observational, Multicenter, Open-label Study of YONDELIS + PLD for the Treatment of Patients With Platinum-sensitive Relapse of Ovarian Cancer

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Apr 2017

At a glance

  • Drugs Trabectedin (Primary) ; Doxorubicin liposomal
  • Indications Ovarian cancer
  • Focus Adverse reactions
  • Acronyms NIS-OvaYond
  • Sponsors PharmaMar
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 24 Mar 2016 Planned End Date changed from 1 Feb 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top